Here is where they still fail to acknowledge the real facts:
GS patients are unable to tolerate gluten and develop an adverse reaction when eating gluten that usually, and differently from CD, does not lead to damage in the small intestine. While the gastrointestinal symptoms in GS may resemble those associated with CD, the overall clinical picture is not accompanied by the concurrence of tTG autoantibodies or other specific celiac-related antibodies. Currently the diagnosis is made by exclusion, and an elimination diet and 'open challenge' (that is, the monitored reintroduction of gluten-containing foods) are most often used to evaluate whether health improves with the elimination of or reduction in gluten from the diet. However, this approach lacks specificity and is subject to the risk of a placebo effect of the elimination diet in improving symptoms.
Despite their continued denial, non-celiac gluten sensitivity does indeed cause damage in the small intestine. While it doesn't typically cause villus atrophy, it does almost always involve inflammation due to lymphocytic infiltration at the villus tips. This is still very real damage, just on a microscopic scale.
Also, their denial of the existence of a specific way to diagnose non-celiac gluten sensitivity is a slap in the face of Dr. Fine's work and EnteroLab, because Dr. Fine has clearly shown that non-celiac gluten sensitivity can be easily and reliably diagnosed by means of stool tests. A stool test that results in a positive anti-gliadin antibody result, together with the absence of a celiac gene, appears to constitute an accurate and reliable way to diagnose non-celiac gluten sensitivity. IMO, when they admit this, they will finally become honest researchers.
Tex
